Pemvidutide: trials, results, and current status.
Also searched as ALT-801 · balanced GLP-1/glucagon dual agonist · Altimmune pemvidutide
Pemvidutide, formerly ALT-801, is Altimmune's investigational once-weekly peptide with balanced GLP-1 and glucagon receptor activity. It has a completed Phase 2 obesity record, a completed Phase 2b MASH study, and active studies in alcohol-related conditions. Altimmune plans a multinational MASH Phase 3 trial, but pemvidutide is not FDA approved and has no authenticated retail product or commercial dosing route.
Is pemvidutide in Phase 3 or available now?
Altimmune plans to begin the multinational PERFORMA Phase 3 MASH trial in the second half of 2026. Current records also include completed IMPACT Phase 2b MASH work, an active Phase 2 alcohol-use-disorder study, and a recruiting alcohol-associated-liver-disease study. The FDA designations for MASH and alcohol use disorder are development tools, not approvals. Pemvidutide is not FDA approved and has no legitimate approved retail product, label, commercial price, pharmacy channel, or routine prescribing pathway.
Compare Pemvidutide with Retatrutide, without losing the country context.
Put evidence status, ClinicalTrials.gov coverage, official United States records, and qualified US research prices in one view. Blank fields stay blank when the underlying dataset does not support a number.
Investigational clinical program
Official product and seller records attached
Investigational clinical program
What can you conclude about Pemvidutide today?
These are dated program facts, not a cross-trial ranking, approval forecast, personal treatment recommendation, or proof that a same-name online product is the sponsor's medicine.
Mean change with 2.4 mg versus 2.2% with placebo in 391 adults without diabetes, according to the sponsor report.
Weight change with 1.8 mg in the MASH population, alongside liver and cardiometabolic endpoints.
Breakthrough Therapy for MASH and Fast Track designations for MASH and alcohol use disorder are not approvals.
Altimmune says a multinational MASH Phase 3 trial is planned for the second half of 2026.
Know which molecule the result belongs to.
- Sponsor
- Altimmune
- Mechanism
- Balanced 1:1 GLP-1 and glucagon receptor dual agonist
- Route being studied
- Once-weekly subcutaneous injection
- Current stage
- Phase 2 programs active; MASH Phase 3 planned
- Featured trial anchors
- NCT05989711 · NCT06987513 · NCT07009860 · NCT05006885
- Evidence checked
- July 18, 2026
Pemvidutide weight-loss results, with the trial attached.
This visual shows one selected result, not every dose or endpoint in the program. The percentage remains attached to its duration, population, comparator, analysis method, and source.
Evidence checked July 21, 2026Pemvidutide reported 15.6% mean reduction at 48 weeks under the sponsor-reported 48-week mean. The comparator recorded 2.2% mean reduction.
Bar lengths share a 0 to 30% visual scale. They describe this selected record and do not make separate trials head-to-head.
- Population
- Adults with obesity, or overweight plus a comorbidity
- Participants
- 391 Total randomized trial population
- Dose
- 2.4 mg
- Primary analysis
- Sponsor-reported 48-week mean
- Regulatory status
- Investigational; not FDA approved
Pemvidutide clinical trials by status, phase, and location.
The current exact-intervention snapshot matches 9 unique NCT records. This chart describes registry coverage and current study fields. It does not compare efficacy, safety, approval probability, eligibility, or treatment access.
Snapshot 2026-07-24Counts use individual locations currently marked Recruiting, not every facility listed on an overall-recruiting study. Repeated centers across studies remain repeated site observations.
Pemvidutide across 42 countries.
This profile establishes the program identity and its cited clinical or regulatory record. It does not turn a same-name seller listing into the sponsor’s asset or prove authorization, availability, or lawful supply in another destination.
Compare Pemvidutide by country →Compare Pemvidutide by US state →Browse the global peptide country dataset →Is Pemvidutide approved or available in your country?
Start with the United States FDA record, then check the destination that matters to you. Each country page separates drug identity, authorization, product records, seller claims, and supply rules. Directory checked July 20, 2026.
What the record shows - and what it doesn’t.
Trial percentages are kept beside the design details that make them interpretable. Unknowns stay visible instead of being filled with launch speculation.
MOMENTUM established a substantial obesity signal
The 48-week Phase 2 MOMENTUM trial enrolled 391 adults with obesity, or overweight plus a comorbidity, without diabetes. Altimmune reported mean changes of 10.3%, 11.2%, and 15.6% for weekly 1.2 mg, 1.8 mg, and 2.4 mg pemvidutide versus 2.2% with placebo. The result supports the development history but is not a Phase 3 obesity outcome, an approved indication, or a head-to-head comparison with another drug.
IMPACT addresses a different MASH question
IMPACT randomized 212 people with biopsy-confirmed MASH and F2 or F3 fibrosis to weekly pemvidutide or placebo for 48 weeks. The peer-reviewed 24-week report and sponsor's 48-week update cover liver histology, non-invasive fibrosis measures, cardiometabolic outcomes, and weight. At 48 weeks, Altimmune reported 7.5% weight loss with 1.8 mg and about 1% discontinuation because of adverse events across pemvidutide participants.
Regulatory designations and Phase 3 plans are not approval
The FDA granted Breakthrough Therapy designation for pemvidutide in MASH and Fast Track designations for MASH and alcohol use disorder. Altimmune says PERFORMA is planned as a multinational randomized Phase 3 MASH study in the second half of 2026. A designation can support development and review interactions, but it does not establish efficacy, an approved label, a decision date, market supply, or a commercial product.
No registered PERFORMA outcome exists
The current sponsor plan describes a future MASH Phase 3 trial. Until a registry record and later results are available, enrollment, doses, countries, endpoints, duration, discontinuations, and outcomes remain unconfirmed or incomplete. A planned pivotal study is not evidence that the program will be approved.
No FDA-approved pemvidutide product
Pemvidutide has no FDA-approved indication, prescribing information, application number, final dose, pharmacy presentation, retail price, insurance coverage, or routine clinical supply channel. An online listing using pemvidutide or ALT-801 does not become Altimmune clinical material by sharing a name.
Obesity and MASH percentages cannot be merged
MOMENTUM and IMPACT studied different populations, doses, endpoints, and clinical questions. Their 48-week weight percentages should not be averaged, substituted, or used to rank pemvidutide against survodutide, mazdutide, retatrutide, semaglutide, or another program without a common randomized protocol.
The questions behind the search.
Concise answers based on the dated sponsor and trial records below. This is educational reporting, not medical advice.
What is pemvidutide, and is it the same as ALT-801?
Yes. Pemvidutide is the current name for the Altimmune peptide previously identified as ALT-801. It is designed as a balanced 1:1 agonist of the GLP-1 and glucagon receptors and is administered once weekly by subcutaneous injection in trials. The GLP-1 component is intended to affect appetite and metabolic signalling, while glucagon activity is being studied for direct liver and energy-expenditure effects. Those mechanism claims describe an investigational program, not an approved indication, consumer dose, retail product, or authenticated online vial.
How much weight loss did pemvidutide produce?
In the sponsor-reported 48-week MOMENTUM obesity trial, mean weight loss was 15.6% with the 2.4 mg weekly group versus 2.2% with placebo. In the separate IMPACT MASH study, Altimmune reported 7.5% weight loss with 1.8 mg at week 48. These figures come from different populations and development questions. Neither predicts an individual's result, establishes an approved dose, or creates a fair direct ranking against retatrutide, survodutide, mazdutide, semaglutide, tirzepatide, or another drug.
Is pemvidutide in Phase 3 or available now?
Altimmune plans to begin the multinational PERFORMA Phase 3 MASH trial in the second half of 2026. Current records also include completed IMPACT Phase 2b MASH work, an active Phase 2 alcohol-use-disorder study, and a recruiting alcohol-associated-liver-disease study. The FDA designations for MASH and alcohol use disorder are development tools, not approvals. Pemvidutide is not FDA approved and has no legitimate approved retail product, label, commercial price, pharmacy channel, or routine prescribing pathway.
Do not use an investigational name, trial dose, or online research listing as a substitute for approved care. This page does not recommend treatment, sourcing, or participation in a clinical trial.
Understand the product-category boundary →